PE20090769A1 - Proteinas de union a antigenos que se unen a par-2 - Google Patents

Proteinas de union a antigenos que se unen a par-2

Info

Publication number
PE20090769A1
PE20090769A1 PE2008001101A PE2008001101A PE20090769A1 PE 20090769 A1 PE20090769 A1 PE 20090769A1 PE 2008001101 A PE2008001101 A PE 2008001101A PE 2008001101 A PE2008001101 A PE 2008001101A PE 20090769 A1 PE20090769 A1 PE 20090769A1
Authority
PE
Peru
Prior art keywords
seq
sequence
amino acids
antigen
cdr1
Prior art date
Application number
PE2008001101A
Other languages
English (en)
Inventor
Shaw-Fen Sylvia Hu
G Duke Virca
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20090769A1 publication Critical patent/PE20090769A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDO A UNA PROTEINA DE UNION A ANTIGENO QUE SE UNE ESPECIFICAMENTE AL PAR-2 (RECEPTOR ACTIVADO POR PROTEASA), QUE POSEE UNA CADENA PESADA QUE COMPRENDE UNA REGION VARIABLE DE AL MENOS 95% IDENTICA A LA SEC ID NO:9, Y UNA CADENA LIVIANA QUE COMPRENDE UNA REGION VARIABLE DE AL MENOS 95% IDENTICA A LA SEC ID NO:11; LA CADENA PESADA COMPRENDE: CDR1 CON LA SECUENCIA DE AMINOACIDOS 31 A 35, CDR2 CON LA SECUENCIA DE AMINOACIDOS 50 A 66 Y CDR3 CON LA SECUENCIA DE AMINOACIDOS 99 A 115, DE LAS SEC ID NO:09, SEC ID NO:13 Y SEC ID NO:17; LA CADENA LIVIANA COMPRENDE: CDR1 CON LA SECUENCIA DE AMINOACIDOS 23 A 33, CDR2 CON LA SECUENCIA DE AMINOACIDOS 49 A 55 Y CDR3 CON LA SECUENCIA DE AMINOACIDOS 88 A 97, DE LAS SEC ID NO:11, SEC ID NO:15 Y SEC ID NO:19. TAMBIEN SE REFERE A UN ACIDO NUCLEICO QUE LO CODIFICA, UN VECTOR, UNA CELULA HUESPED, UN METODO DE PRODUCCION Y UNA COMPOSICION CON UN VEHICULO FARMACOLOGICAMENTE ACEPTABLE. DICHA PROTEINA DE UNION A ANTIGENO ES UTIL PARA TRATAR INFLAMACIONES DEL SISTEMA GASTROINTESTINAL, ENFERMEDAD DE CROHN, COLITIS ULCERATIVA, PANCREATITIS, ENFERMEDADES INFLAMATORIAS DE LAS VIAS RESPIRATORIAS, TRASTORNOS REUMATICOS
PE2008001101A 2007-06-29 2008-06-27 Proteinas de union a antigenos que se unen a par-2 PE20090769A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94726407P 2007-06-29 2007-06-29
US5809408P 2008-06-02 2008-06-02

Publications (1)

Publication Number Publication Date
PE20090769A1 true PE20090769A1 (es) 2009-07-23

Family

ID=39718522

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001101A PE20090769A1 (es) 2007-06-29 2008-06-27 Proteinas de union a antigenos que se unen a par-2

Country Status (17)

Country Link
US (3) US8357367B2 (es)
EP (2) EP2562186A1 (es)
JP (1) JP5255633B2 (es)
KR (1) KR20100033523A (es)
CN (1) CN101743254A (es)
AR (1) AR067199A1 (es)
AU (1) AU2008271073B2 (es)
BR (1) BRPI0813242A2 (es)
CA (1) CA2690538A1 (es)
CL (1) CL2008001887A1 (es)
EA (1) EA200901436A1 (es)
ES (1) ES2406429T3 (es)
IL (1) IL202259A0 (es)
MX (1) MX2009013824A (es)
PE (1) PE20090769A1 (es)
TW (1) TW200909447A (es)
WO (1) WO2009005726A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100119506A1 (en) * 2008-08-05 2010-05-13 Boehringer Ingelheim International Gmbh Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015048245A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
SG11201908328XA (en) 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
US10836822B2 (en) * 2017-03-16 2020-11-17 Medimmune Limited Anti-PAR2 antibodies and uses thereof
US11304966B2 (en) * 2017-12-22 2022-04-19 Glycom A/S Composition comprising HMOs for preventing or reducing nociception
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
US20220193048A1 (en) 2019-04-05 2022-06-23 Universite De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4200018A1 (en) * 2020-08-18 2023-06-28 Cephalon LLC Anti-par-2 antibodies and methods of use thereof
WO2022081824A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5716789A (en) 1993-07-26 1998-02-10 Cor Therapeutics, Inc. Method to determine ligands, agonist and antagonist of C140 receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
AU2001231030A1 (en) 2000-01-20 2001-07-31 Amgen Inc Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2004080373A2 (en) 2003-03-11 2004-09-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20070098715A1 (en) 2005-03-25 2007-05-03 Seth Ettenberg Antibodies against the tenascin major antigens
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2

Also Published As

Publication number Publication date
EP2167543B1 (en) 2013-04-03
JP5255633B2 (ja) 2013-08-07
CN101743254A (zh) 2010-06-16
WO2009005726A1 (en) 2009-01-08
MX2009013824A (es) 2010-04-12
TW200909447A (en) 2009-03-01
BRPI0813242A2 (pt) 2015-08-18
EP2562186A1 (en) 2013-02-27
CA2690538A1 (en) 2009-01-08
ES2406429T3 (es) 2013-06-07
CL2008001887A1 (es) 2008-10-03
KR20100033523A (ko) 2010-03-30
US8470556B2 (en) 2013-06-25
IL202259A0 (en) 2010-06-16
JP2010532165A (ja) 2010-10-07
US20130011878A1 (en) 2013-01-10
US20110059063A1 (en) 2011-03-10
AU2008271073B2 (en) 2012-05-03
AU2008271073A1 (en) 2009-01-08
US8357367B2 (en) 2013-01-22
US20140170166A1 (en) 2014-06-19
EA200901436A1 (ru) 2010-10-29
AR067199A1 (es) 2009-09-30
EP2167543A1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
PE20090769A1 (es) Proteinas de union a antigenos que se unen a par-2
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
RU2505603C2 (ru) Антитело против рецептора il-6
JP2018033454A5 (es)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
PE20141658A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
PE20141162A1 (es) Anticuerpos anti-il-23
JP2017515909A5 (es)
PE20081625A1 (es) Proteinas de union al antigeno del receptor a de la il-17
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
PE20121691A1 (es) Formulacion de anticuerpos y regimenes terapeuticos
AR073978A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
EA201200277A1 (ru) Антитела против респираторного синцитиального вируса (pcb) и способы их применения
CN108473563B (zh) 改进的tnf结合剂
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
PE20140247A1 (es) Anticuerpos anti-cd38
PE20140218A1 (es) Composicion farmaceutica

Legal Events

Date Code Title Description
FC Refusal